Anti-cytotoxic T lymphocyte antigen-4 antibodies in melanoma

References

• KormanAJPeggsKSAllisonJPCheckpoint blockade in cancer immunotherapyAdv Immunol20069029733916730267
   PubMed Web of Science ®Google Scholar
• HwuPTreating cancer by targeting the immune systemN Engl J Med201019363(8)77978120818880
   PubMed Web of Science ®Google Scholar
• ChambersCAKuhnsMSEgenJGAllisonJPCTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapyAnnu Rev Immunol20011956559411244047
   PubMed Web of Science ®Google Scholar
• LinsleyPSGreeneJLTanPCoexpression and functional cooperation of CTLA-4 and CD28 on activated T lymphocytesJ Exp Med19921766159516041334116
   PubMed Web of Science ®Google Scholar
• KrummelMFAllisonJPCD28 and CTLA-4 have opposing effects on the response of T cells to stimulationJ Exp Med199518224594657543139
   PubMed Web of Science ®Google Scholar
• KearneyERWalunasTLKarrRWAntigen-dependent clonal expansion of a trace population of antigen-specific CD4+ T cells in vivo is dependent on CD28 costimulation and inhibited by CTLA-4J Immunol19951553103210367543510
   PubMed Web of Science ®Google Scholar
• WalunasTLLenschowDJBakkerCYCTLA-4 can function as a negative regulator of T cell activationImmunity1994154054137882171
   PubMed Web of Science ®Google Scholar
• KrummelMFSullivanTJAllisonJPSuperantigen responses and costimulation: CD28 and CTLA-4 have opposing effects on T cell expansion in vitro and in vivoInt Immunol1996845195238671638
   PubMed Web of Science ®Google Scholar
• TivolEABorrielloFSchweitzerANLynchWPBluestoneJASharpeAHLoss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4Immunity199535415477584144
   PubMed Web of Science ®Google Scholar
• WaterhousePPenningerJMTimmsELymphoproliferative disorders with early lethality in mice deficient in CTLA-4Science19952709859887481803
   PubMed Web of Science ®Google Scholar
• ChambersCACadoDTruongTAllisonJPThymocyte development is normal in CTLA-4-deficient miceProc Natl Acad Sci U S A199794929693019256476
   PubMed Web of Science ®Google Scholar
• WaterhousePBachmannMFPenningerJMOhashiPSMakTWNormal thymic selection, normal viability and decreased lymphopro-liferation in T cell receptor-transgenic CTLA-4-deficient miceEur J Immunol1997278188718929295023
   PubMed Web of Science ®Google Scholar
• MeleroIHervas-StubbsSGlennieMPardollDMChenLImmunostimulatory monoclonal antibodies for cancer therapyNat Rev Cancer2007729510617251916
   PubMed Web of Science ®Google Scholar
• ThompsonCBAllisonJPThe emerging role of CTLA-4 as an immune attenuatorImmunity1997744454509354465
   PubMed Web of Science ®Google Scholar
• de la Cruz-MerinoLGrande-PulidoEAlbero-TamaritACodesManuel de VillenaMECancer and immune response: old and new evidence for future challengesOncologist200813121246125419056856
   PubMed Web of Science ®Google Scholar
• AlegreMLFallarinoFMechanisms of CTLA-4-Ig in tolerance inductionCurr Pharm Des200612214916016454732
   PubMed Web of Science ®Google Scholar
• HoosAIbrahimRKormanADevelopment of ipilimumab: contribution to a new paradigm for cancer immunotherapySemin Oncol201037553354621074069
   PubMed Web of Science ®Google Scholar
• KrummelMFAllisonJPCTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cellsJ Exp Med19961836253325408676074
   PubMed Web of Science ®Google Scholar
• BrunnerMCChambersCAChanFKHankeJWinotoAAllisonJPCTLA-4-Mediated inhibition of early events of T cell proliferationJ Immunol1999162105813582010229815
   PubMed Web of Science ®Google Scholar
• YangYZouJMuJEnhanced induction of antitumor T-cell responses by cytotoxic T lymphocyte associated molecule-4 blockade: the effect is manifested only at the restricted tumor-bearing stagesCancer Res199757403640419307290
   PubMed Web of Science ®Google Scholar
• ShrikantPKhorutsAMescherMFCTLA-4 blockade reverses CD8C T cell tolerance to tumor by a CD4CT cell and IL-2 dependent mechanismImmunity19991148349310549630
   PubMed Web of Science ®Google Scholar
• SotomayorEMBorrelloIMTubbEAllisonJPLevitskyHIIn vivo blockade of CTLA-4 enhances the priming of responsive T-cells but fails to prevent the induction of tumor antigen-specific toleranceProc Natl Acad Sci U S A19999620114761148110500201
   PubMed Web of Science ®Google Scholar
• LeachDRKrummelMFAllisonJPEnhancement of antitumor immunity by CTLA-4 blockadeScience19962715256173417368596936
   PubMed Web of Science ®Google Scholar
• DranoffGJaffeeELazenbyAVaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting antitumor immunityProc Natl Acad Sci U S A199390353935438097319
   PubMed Web of Science ®Google Scholar
• van ElsasAHurwitzAAAllisonJPCombination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentationJ Exp Med1999190335536610430624
   PubMed Web of Science ®Google Scholar
• HurwitzAAYuTFLeachDRAllisonJPCTLA-4 blockade synergizes with tumor-derived granulocyte-macrophage colony-stimulating factor for treatment of an experimental mammary carcinomaProc Natl Acad Sci U S A1998951710067100719707601
   PubMed Web of Science ®Google Scholar
• HurwitzAAFosterBAKwonEDCombination immunotherapy of primary prostate cancer in a transgenic mouse model using CTLA-4 blockadeCancer Res20006092444244810811122
   PubMed Web of Science ®Google Scholar
• GregorPDWolchokJDFerroneCRCTLA-4 blockade in combination with xenogeneic DNA vaccines enhances T-cell responses, tumor immunity and autoimmunity to self antigens in animal and cellular model systemsVaccine20042213–141700170815068853
   PubMed Web of Science ®Google Scholar
• DavilaEKennedyRCelisEGeneration of antitumor immunity by cytotoxic T lymphocyte epitope peptide vaccination, CpG-oligodeoxynucleotide adjuvant, and CTLA-4 blockadeCancer Res200363123281328812810660
   PubMed Web of Science ®Google Scholar
• ChambersCASullivanTJAllisonJPLymphoproliferation in CTLA-4-deficient mice is mediated by costimulation-dependent activation of CD4+ T cellsImmunity1997768858959430233
   PubMed Web of Science ®Google Scholar
• ChambersCASullivanTJTruongTAllisonJPSecondary but not primary T cell responses are enhanced in CTLA-4-deficient CD8+ T cellsEur J Immunol19982810313731439808182
   PubMed Web of Science ®Google Scholar
• McCoyKDHermansIFFraserJHLe GrosGRoncheseFCytotoxic T lymphocyte-associated antigen 4 (CTLA-4) can regulate dendritic cell-induced activation and cytotoxicity of CD8(+) T cells independently of CD4(+) T cell helpJ Exp Med199918971157116210190907
   PubMed Web of Science ®Google Scholar
• PeggsKSQuezadaSAChambersCAKormanAJAllisonJPBlockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodiesJ Exp Med200920681717172519581407
   PubMed Web of Science ®Google Scholar
• KaehlerKCPielSLivingstoneESchillingBHauschildASchadendorfDUpdate on immunologic therapy with anti-CTLA-4 antibodies in melanoma: identification of clinical and biological response patterns, immune-related adverse events, and their managementSemin Oncol201037548549821074064
   PubMed Web of Science ®Google Scholar
• RibasAClinical development of the anti-CTLA-4 antibody tremelimumabSemin Oncol201037545045421074059
   PubMed Web of Science ®Google Scholar
• CamachoLHAntoniaSSosmanJPhase I/II trial of tremelimumab in patients with metastatic melanomaJ Clin Oncol20092771075108119139427
   PubMed Web of Science ®Google Scholar
• WeberJIpilimumab: controversies in its development, utility and autoimmune adverse eventsCancer Immunol Immunother200958582383019198837
   PubMed Web of Science ®Google Scholar
• AttiaPPhanGQMakerAVAutoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4J Clin Oncol200523256043605316087944
   PubMed Web of Science ®Google Scholar
• MakerAVYangJCSherryRMIntrapatient dose escalation of anti-CTLA-4 antibody in patients with metastatic melanomaJ Immunother200629445546316799341
   PubMed Web of Science ®Google Scholar
• WeberJSO’DaySUrbaWPhase I/II study of ipilimumab for patients with metastatic melanomaJ Clin Oncol200826365950595619018089
   PubMed Web of Science ®Google Scholar
• HodiFSButlerMObleDAImmunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patientsProc Natl Acad Sci U S A200810583005301018287062
   PubMed Web of Science ®Google Scholar
• WolchokJDKlugerHCallahanMKNivolumab plus ipilimumab in advanced melanomaN Engl J Med2013369212213323724867
   PubMed Web of Science ®Google Scholar
• TopalianSLHodiFSBrahmerJRSafety, activity, and immune correlates of anti-PD-1 antibody in cancerN Engl J Med20123662443245422658127
   PubMed Web of Science ®Google Scholar
• WolchokJDNeynsBLinetteGIpilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging studyLancet Oncol201011215516420004617
   PubMed Web of Science ®Google Scholar
• O’DaySJMaioMChiarion-SileniVEfficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II studyAnn Oncol20102181712171720147741
   PubMed Web of Science ®Google Scholar
• WeberJThompsonJAHamidOA randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanomaClin Cancer Res200915175591559819671877
   PubMed Web of Science ®Google Scholar
• KornELLiuPYLeeSJMeta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trialsJ Clin Oncol200826452753418235113
   PubMed Web of Science ®Google Scholar
• MargolinKErnstoffMSHamidOIpilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trialLancet Oncol201213545946522456429
   PubMed Web of Science ®Google Scholar
• Di GiacomoAMAsciertoPAPillaLIpilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trialLancet Oncol201213987988622894884
   PubMed Web of Science ®Google Scholar
• HodiFSO’DaySJMcDermottDFImproved survival with ipilimumab in patients with metastatic melanomaN Engl J Med2010363871172320525992
   PubMed Web of Science ®Google Scholar
• HoosAEggermontAMJanetzkiSImproved endpoints for cancer immunotherapy trialsJ Natl Cancer Inst2010102181388139720826737
   PubMed Web of Science ®Google Scholar
• RobertCHodiFSO’DayRe-induction with ipilimumab, gp100 peptide vaccine or a combination of both in a Phase III study of previously-treated patients with advanced melanoma: update of clinical characteristic of patients35th Congress of the European Society for Medical Oncology (ESMO)October 8–10, 2010Milan, Italy
   Google Scholar
• SchwartzentruberDJLawsonDHRichardsJMgp100 peptide vaccine and interleukin-2 in patients with advanced melanomaN Engl J Med2011364222119212721631324
   PubMed Web of Science ®Google Scholar
• PrietoPAYangJCSherryRMCTLA-4 blockade with ipilimumab: long-term follow-up of 177 patients with metastatic melanomaClin Cancer Res20121872039204722271879
   PubMed Web of Science ®Google Scholar
• RobertCThomasLBondarenkoIIpilimumab plus dacarbazine for previously untreated metastatic melanomaN Engl J Med2011364262517252621639810
   PubMed Web of Science ®Google Scholar
• AlmubarakMAbrahamJResearch highlights: highlights from the latest articles in cancer immunotherapyImmunotherapy20124547347522642329
   PubMed Web of Science ®Google Scholar
• ClinicalTrialsgov [homepage on the Internet]National Institutes of Health Available from: http://www.clinicaltrials.govAccessed July 23, 2013
   Google Scholar
• RibasAChmielowskiBGlaspyJADo we need a different set of response assessment criteria for tumor immunotherapy?Clin Cancer Res200915237116711819934296
   PubMed Web of Science ®Google Scholar
• RibasAComin-AnduixBEconomouJSIntratumoral immune cell infiltrates, FoxP3, and indoleamine 2,3-dioxygenase in patients with melanoma undergoing CTLA4 blockadeClin Cancer Res20091539039919118070
   PubMed Web of Science ®Google Scholar
• WolchokJDHoosAO’DaySGuidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteriaClin Cancer Res2009157412742019934295
   PubMed Web of Science ®Google Scholar
• van ElsasASutmullerRPHurwitzAAElucidating the autoimmune and antitumor effector mechanisms of a treatment based on cytotoxic T lymphocyte antigen-4 blockade in combination with a B16 melanoma vaccine: comparison of prophylaxis and therapyJ Exp Med2001194448148911514604
   PubMed Web of Science ®Google Scholar
• MakerAVPhanGQAttiaPTumor regression and autoim-munity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I/II studyAnn Surg Oncol200512121005101616283570
   PubMed Web of Science ®Google Scholar
• DowneySGKlapperJASmithFOPrognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockadeClin Cancer Res20071322 Pt 16681668817982122
   PubMed Web of Science ®Google Scholar
• KuGYYuanJPageDBSingle-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: lymphocyte count after 2 doses correlates with survivalCancer201011671767177520143434
   PubMed Web of Science ®Google Scholar
• YangAKendleRFGinsbergBACTLA-4 blockade with ipilimumab increases peripheral CD8+ cells: correlation with clinical outcomesJ Clin Oncol20102815s (suppl; abstract 2555)
   PubMed Web of Science ®Google Scholar
• MarshallMARibasAHuangBEvaluation of baseline serum C-reactive protein (CRP) and benefit from tremelimumab compared to chemotherapy in first-line melanomaJ Clin Oncol20102815s (suppl; abstract 2609)
   Web of Science ®Google Scholar
• HamidOSchmidtHNissanAA prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanomaJ Transl Med2011920422123319
   PubMed Web of Science ®Google Scholar
• CetindereTNambiarSSantourlidisSEssmannFHassanMInduction of indoleamine 2, 3-dioxygenase by death receptor activation contributes to apoptosis of melanoma cells via mitochondrial damage-dependent ROS accumulationCell Signal201022219721119799997
   PubMed Web of Science ®Google Scholar
• ObleDALoeweRYuPMihmMCJrFocus on TILs: prognostic significance of tumor infiltrating lymphocytes in human melanomaCancer Immun20099319338264
   PubMedGoogle Scholar
• LiakouCIKamatATangDNCTLA-4 blockade increases IFN-gamma-producing CD4+ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patientsProc Natl Acad Sci U S A2008105149871499218818309
   PubMed Web of Science ®Google Scholar
• CarthonBCWolchokJDYuanJPreoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trialClin Cancer Res201016102861267120460488
   PubMed Web of Science ®Google Scholar
• FuTHeQSharmaPThe ICOS/ICOSL pathway is required for optimal antitumor responses mediated by anti-CTLA-4 therapyCancer Res201171165445545421708958
   PubMed Web of Science ®Google Scholar
• VerschraegenCThe monoclonal antibody to cytotoxic T lymphocyte antigen 4, ipilimumab, in the treatment of melanomaCancer Manag Res201241822346364
   PubMedGoogle Scholar